Betty D.  Larson net worth and biography

Betty Larson Biography and Net Worth

Betty Larson serves as executive vice president and chief human resources officer (CHRO) of BD (Becton, Dickinson and Company), a leading global medical technology company headquartered in Franklin Lakes, New Jersey. She is also a member of the BD Executive Leadership Team.

Larson previously served as senior vice president (SVP) of Human Resources for the company’s Interventional segment, its Greater Asia region and innovation-related functions including Research & Development and BD Medical. She also served as CHRO for C. R. Bard, Inc., a leading medical technology company in the fields of vascular, urology and surgical specialty products, which was acquired by BD in 2017.

Larson started her career at Baxter International, a surgical innovation company where she held multiple positions of increasing responsibility over her 16-year tenure. Most recently, she served as SVP of Human Resources and provided strategic leadership to Baxter’s $10 billion Medical Products segment, in addition to its Global Manufacturing and Research and Development functions.

Larson has cultivated extensive experience in guiding companies through human resources-related challenges and opportunities created by mergers and acquisitions. Over the course of her career, she has earned global responsibility for key human resources processes and focus areas, including leadership succession, talent management, culture change and inclusion and diversity.

Larson serves on the board of directors for Baxter Credit Union and the Overlook Foundation, a non-profit organization that raises funds to support New Jersey-based Overlook Medical Center in its mission to provide high-quality care to patients. She earned a bachelor’s degree in psychology and a master’s degree in human resources from the University of Illinois, and a master’s degree in business administration from Northwestern University.

What is Betty D. Larson's net worth?

The estimated net worth of Betty D. Larson is at least $2.69 million as of May 13th, 2019. Mr. Larson owns 11,493 shares of Becton, Dickinson and Company stock worth more than $2,686,259 as of April 24th. This net worth evaluation does not reflect any other assets that Mr. Larson may own. Learn More about Betty D. Larson's net worth.

How do I contact Betty D. Larson?

The corporate mailing address for Mr. Larson and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on Betty D. Larson's contact information.

Has Betty D. Larson been buying or selling shares of Becton, Dickinson and Company?

Betty D. Larson has not been actively trading shares of Becton, Dickinson and Company during the last ninety days. Most recently, Betty D. Larson sold 14,374 shares of the business's stock in a transaction on Friday, February 25th. The shares were sold at an average price of $271.90, for a transaction totalling $3,908,290.60. Learn More on Betty D. Larson's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, insiders at the medical instruments supplier sold shares 6 times. They sold a total of 8,019 shares worth more than $2,132,768.00. The most recent insider tranaction occured on March, 14th when SVP Thomas J Spoerel sold 282 shares worth more than $67,197.78. Insiders at Becton, Dickinson and Company own 0.3% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 3/14/2024.

Betty D. Larson Insider Trading History at Becton, Dickinson and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/25/2022Sell14,374$271.90$3,908,290.60View SEC Filing Icon  
12/16/2021Sell3,341$255.00$851,955.00View SEC Filing Icon  
5/13/2019Sell1,700$224.97$382,449.0011,493View SEC Filing Icon  
See Full Table

Betty D. Larson Buying and Selling Activity at Becton, Dickinson and Company

This chart shows Betty D Larson's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $233.73
Low: $230.03
High: $234.57

50 Day Range

MA: $239.62
Low: $231.01
High: $247.45

2 Week Range

Now: $233.73
Low: $229.40
High: $287.32

Volume

779,835 shs

Average Volume

1,381,389 shs

Market Capitalization

$67.52 billion

P/E Ratio

55.39

Dividend Yield

1.62%

Beta

0.43